Market Overview

UPDATE: Stifel Nicolaus Initiates Geron Corporation at Buy with $4 PT; Oncology Refocus Paying Off

Related GERN
Geron Corp. (GERN) Jumps: Stock Moves 8.1% Higher - Tale of the Tape
Geron Falls: Stock Goes Down 5.4% - Tale Of The Tape

Stifel Nicolaus initiated coverage on Geron Corporation (NASDAQ: GERN) with a Buy rating and a price target of $4 a share.

Stifel Nicolaus noted, "We anticipate positive proof-of-concept data for Geron's two oncology assets to reignite investor interest. In our opinion, six Phase 2 data readouts over the next six to nine months should validate Imetelstat and GRN1005 as compelling, differentiated oncology clinical candidates with large commercial opportunities. We believe positive news flow will yield significant stock price appreciation for GERN."

Geron Corporation closed at $2.44 on Wednesday.

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GERN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters